Cepheid announced it has received clearance from the Food and Drug Administration (FDA) to market Xpert Norovirus, an in vitro diagnostic test for identification and differentiation of Noroviruses genogroup I and II.
The Xpert Norovirus allows on-demand detection and differentiation between genogroups I and II, which contribute to the majority of human infections. Healthcare professionals can obtain accurate results within one hour.
The Xpert Norovirus, as well as the recently approved Xpert Flu/RSV XC, run on the company’s GeneXpert system. The test will begin shipping this month.
For more information call (888) 838-3222 or visit Cepheid.com.